keyword
MENU ▼
Read by QxMD icon Read
search

CD30

keyword
https://www.readbyqxmd.com/read/29052238/frequent-expression-of-cd30-in-extranodal-nk-t-cell-lymphoma-potential-therapeutic-target-for-anti-cd30-antibody-based-therapy
#1
Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki, Yuya Sasaki, Kyohei Yamada, Eriko Yanagida, Reiji Muto, Maiko Kiryu, Hirohito Sone, Masao Seto, Koichi Ohshima, Jun Takizawa
Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is a subtype of non-Hodgkin lymphoma with a poor prognosis. Although first-line treatments for patients with localized ENKTL have been established, there is no gold standard treatment for patients with advanced ENKTL and refractory and/or relapsed disease. Anti-CD30 antibody-based therapy, including brentuximab vedotin (BV), has been shown to target malignant lymphomas with CD30 expression. In particular, this therapeutic agent has recently been suggested to be effective for Hodgkin lymphoma and mature T-cell lymphoma...
October 20, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/29051894/a-diagnostic-surprise-primary-hodgkin-s-lymphoma-of-the-lung
#2
Ankur Sinha, Ravikaran Patti, Prabhsimranjot Singh, William Solomon, Yizhak Kupfer
An 81-year-old male presented to the emergency room with a 3-month history of progressive shortness of breath, productive cough with white sputum, and generalized weakness with 10-pound weight loss in 2 months. On presentation, the patient was afebrile, with blood pressure of 93/55 mm Hg and oxy-hemoglobin saturation of 92% on 2 liters of oxygen via nasal cannula. Complete blood count with differential was significant for white count of 12 400/mL. Brain natriuretic peptide level was 454 ng/mL. Postero-anterior chest radiograph showed multiple round opacities in the lung fields...
October 2017: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/29050074/-clinicopathologic-characteristics-and-prognosis-of-neoplastic-cell-rich-mixed-cellularity-classic-hodgkin-lymphoma
#3
W H Hou, P Wei, J L Xie, Y Y Zheng, X G Zhou
Objective: To investigate the clinicopathologic characteristics of neoplastic cell-rich mixed cellularity classical Hodgkin lymphoma(MCCHL-R) and to compare the prognosis with typical mixed cellularity classic Hodgkin lymphoma(MCCHL). Methods: Fifty-four patients with MCCHL-R(the tumor cells >10%) and 65 patients with typical MCCHL identified from 1 721 Hodgkin lymphomas were reviewed to compare the clinicopathological characteristics including morphologic and immunophenotypic features, EBV infection status, clinical therapy and overall survival...
October 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29049466/breast-implant-associated-anaplastic-large-cell-lymphoma-a-systematic-review
#4
Ashley N Leberfinger, Brittany J Behar, Nicole C Williams, Kevin L Rakszawski, John D Potochny, Donald R Mackay, Dino J Ravnic
Importance: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare peripheral T-cell lymphoma, is increasing in incidence. However, many practitioners who treat patients with breast cancer are not aware of this disease. Objectives: To assess how BIA-ALCL develops, its risk factors, diagnosis, and subsequent treatment and to disseminate information about this entity to the medical field. Evidence Review: A literature review was performed in an academic medical setting...
October 18, 2017: JAMA Surgery
https://www.readbyqxmd.com/read/29037766/frequency-and-markers-of-precursor-lesions-and-implications-for-the-pathogenesis-of-testicular-germ-cell-tumors
#5
Finn Edler von Eyben, Marie Bjødstrup Jensen, Søren Høyer
BACKGROUND: The World Health Organization classification of urologic cancer 2016 describes 3 noninvasive precursor lesions for testicular germ cell tumor type II (TGCT) of young adults. Germ cell neoplasia in situ is the initial precursor lesion. Intratubular seminoma (ITSE), and intratubular embryonal carcinoma (ITEC) are 2 intermediate precursor lesions. Microinvasive testicular germ cell tumor (MGCT) is an invasive precursor lesion. MATERIALS AND METHODS: We undertook a retrospective study of testes obtained using orchiectomy for TGCT and examined precursor lesions...
September 5, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29036941/breast-implant-associated-anaplastic-large-cell-lymphoma-in-a-transgender-woman
#6
Mintsje de Boer, Wouter B van der Sluis, Jan P de Boer, Lucy I H Overbeek, Flora E van Leeuwen, Hinne A Rakhorst, René R W J van der Hulst, Nathalie J Hijmering, Mark-Bram Bouman, Daphne de Jong
Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare but serious complication in patients with breast implants, Patients are at risk of BIA-ALCL whether they receive breast implants for cosmetic reasons or for reconstructive purposes after surgery for breast cancer or prophylactic mastectomy. During the past decade, an increased number of reports have addressed BIA-ALCL. Herein, we describe BIA-ALCL in a transgender woman. The patient received breast implants as part of her gender transition and was diagnosed with BIA-ALCL 20 years later...
September 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/29025292/-brentuximab-vedotin-treatment-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma-a-hungarian-retrospective-study
#7
Zsuzsa Molnár, László Imre Pinczés, Klára Piukovics, Ildikó Istenes, Krisztina Wolf, Zoltán Csukly, Árpád Szomor, Árpád Illés, Zsófia Miltényi
INTRODUCTION: The treatment of relapsed or refractory Hodgkin lymphoma is still a major therapeutic challenge. The use of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, represents a promising approach for these patients, however clinical outcomes have not yet been evaluated in Hungary. AIM: Our aim was to assess the efficacy, safety and outcome of brentuximab vedotin treatment in Hungarian Hodgkin lymphoma patients. METHOD: In this retrospective case note review we enrolled patients at 6 clinical sites countrywide who were diagnosed with Hodgkin lymphoma and received brentuximab vedotin between 1 January 2013 and 31 December 2016...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28993768/cd30-is-dispensable-for-t-cell-responses-to-influenza-virus-and-lymphocytic-choriomeningitis-virus-clone-13-but-contributes-to-age-associated-t-cell-expansion-in-mice
#8
Angela C Zhou, Laura M Snell, Michael E Wortzman, Tania H Watts
CD30 is a tumor necrosis factor receptor (TNFR) family member whose expression is associated with Hodgkin's disease, anaplastic large cell lymphomas, and other T and B lymphoproliferative disorders in humans. A limited number of studies have assessed the physiological role of CD30/CD30 ligand interactions in control of infection in mice. Here, we assess the role of CD30 in T-cell immunity to acute influenza and chronic lymphocytic choriomeningitis virus (LCMV) clone 13 infection, two viral infections in which other members of the TNFR superfamily are important for T-cell responses...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28982264/de-novo-unclassifiable-cd20-negative-diffuse-large-b-cell-lymphoma-a-diagnostic-and-therapeutic-challenge
#9
Badr AbdullGaffar, Rania M Seliem
CD20-negative diffuse large B-cell lymphomas (DLBCLs) constitute a rare and heterogeneous group of aggressive lymphomas. Known well-documented variants include plasmablastic lymphomas, primary effusion lymphomas, anaplastic kinase-positive large B-cell lymphomas, and large B-cell lymphomas arising in human herpesvirus 8 (HHV8)-associated multicentric Castleman disease. They impose diagnostic challenges for pathologists and therapeutic confrontations for clinicians. CD20 loss in B-cell lymphomas is a well-known phenomenon after rituximab therapy...
October 1, 2017: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28980004/brentuximab-vedotin-for-patients-with-refractory-lymphomatoid-papulosis-an-analysis-of-phase-2-results
#10
Daniel J Lewis, Rakhshandra Talpur, Auris O Huen, Michael T Tetzlaff, Madeleine Duvic
Importance: Brentuximab vedotin is a monomethyl auristatin E-conjugated monoclonal antibody directed against CD30. It represents a potential treatment for the CD30+ lymphoproliferative disorder lymphomatoid papulosis (LyP), which currently has no approved treatment. Objective: To assess the efficacy and safety of brentuximab vedotin for the treatment of LyP. Design, Setting, and Participants: In this study conducted at The University of Texas MD Anderson Cancer Center from May 10, 2011, to March 31, 2017, a total of 12 patients with LyP received brentuximab vedotin...
October 4, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28978839/treatment-strategy-for-patients-with-hodgkin-lymphoma
#11
Isao Yoshida
Although Hodgkin lymphoma is a disease with a low incidence rate, there is a significant social resources perspective associated with this disease to ensure that adolescents and young adults are adequately treated and receive social reintegration. Consequently, Hodgkin lymphoma is considered an important disease in the field of oncology. Combined modality therapy, which combines chemotherapy and radiotherapy, has resulted in cure rates of more than 80% in patients with early stages of this disease, although long-term sequelae remain a problem...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28978570/enhancer-profiling-identifies-critical-cancer-genes-and-characterizes-cell-identity-in-adult-t-cell-leukemia
#12
Regina Wan Ju Wong, Phuong Cao Thi Ngoc, Wei Zhong Leong, Alice Wei Yee Yam, Tinghu Zhang, Kaori Asamitsu, Shinsuke Iida, Takashi Okamoto, Ryuzo Ueda, Nathanael S Gray, Takashi Ishida, Takaomi Sanda
A number of studies have recently demonstrated that "super-enhancers", which are large cluster of enhancers typically marked by a high level of acetylation of histone H3 lysine 27 and mediator bindings, are frequently associated with genes that control and define cell identity during normal development. Super-enhancers are also often enriched at cancer genes in various malignancies. Identification of such enhancers would pinpoint critical factors that directly contribute to pathogenesis. Here, we performed enhancer profiling using primary leukemia samples from adult T-cell leukemia/lymphoma (ATL), which is a genetically heterogeneous intractable cancer...
October 4, 2017: Blood
https://www.readbyqxmd.com/read/28976934/restoration-of-dap-kinase-tumor-suppressor-function-a-therapeutic-strategy-to-selectively-induce-apoptosis-in-cancer-cells-using-immunokinase-fusion-proteins
#13
REVIEW
Mehmet Kemal Tur, Adebukola K Daramola, Stefan Gattenlöhner, Marco Herling, Shivan Chetty, Stefan Barth
Targeted cancer immunotherapy is designed to selectively eliminate tumor cells without harming the surrounding healthy tissues. The death-associated protein kinases (DAPk) are a family of proapoptotic proteins that play a vital role in the regulation of cellular process and have been identified as positive mediators of apoptosis via extrinsic and intrinsic death-regulating signaling pathways. Tumor suppressor activities have been shown for DAPk1 and DAPk2 and they are downregulated in e.g., Hodgkin's (HL) and B cell lymphoma (CLL), respectively...
October 4, 2017: Biomedicines
https://www.readbyqxmd.com/read/28976132/diffuse-large-b-cell-lymphoma-of-hard-palate-a-case-report-with-literature-review
#14
Bhavana Rai, Madhusudan S Astekar, Bhari Sharanesha Manjunatha, Gaurav Sapra
Lymphomas are diverse group of neoplasm affecting the lymphoreticular system. Diffuse large B cell lymphoma is the most frequently diagnosed type of non-Hodgkin lymphoma and is the fifth most frequent malignancy, accounting for about 40% of cases reported. In the present case report a 40 year old female patient complains of swelling on right side of face since 45 days and gradually increased to present size. Intra-orally an ulcero-proliferative growth was present on the right side of hard palate. Incisional biopsy was suggestive of Lymphoproliferative disorder...
September 2017: Journal of Experimental Therapeutics & Oncology
https://www.readbyqxmd.com/read/28975123/systemic-and-primary-cutaneous-anaplastic-large-cell-lymphoma-clinical-features-morphological-spectrum-and-immunohistochemical-profile
#15
Kanwardeep Singh Kwatra, Preethi A M Paul, Nalini Calton, Joseph M John, James D Cotelingam
BACKGROUND: T-cell lymphomas with anaplastic morphology typically comprise of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma (ALK+ ALCL), ALK-negative ALCL (ALK- ALCL), and primary cutaneous ALCL (PC-ALCL). However, other entities such as diffuse large B-cell lymphoma, peripheral T-cell lymphoma, Hodgkin lymphoma, and undifferentiated carcinoma can also show similar anaplastic features. AIMS: To study the clinical features and histological spectrum of ALCL and emphasize the role of immunohistochemistry (IHC) in their diagnosis and categorization...
July 2017: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28965629/cd30-t-cell-enriched-primary-cutaneous-cd4-small-medium-sized-pleomorphic-t-cell-lymphoma-a-distinct-variant-of-indolent-cd4-t-cell-lymphoproliferative-disease
#16
REVIEW
Cynthia M Magro, Luke C Olson, Clifton G Fulmer
Primary cutaneous CD4+ small/medium sized pleomorphic T-cell lymphoma (SMPTCL) is unique among the peripheral T-cell lymphomas because of its indolent nature, typically presenting as a solitary nodule or plaque in the head and neck area of middle-aged and older adults. Recent studies have suggested a follicular helper cell origin for these lesions. MATERIALS AND METHODS: A retrospective review was conducted on all cases of SMPTCL diagnosed between 2008 and 2017. The goal of our study was to better categorize the clinical, pathologic and molecular features of cases of SMPTCL showing a significant degree of CD30 neoplastic large cell infiltration...
October 2017: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/28961300/traumatic-ulcerative-granuloma-with-stromal-eosinophilia-a-malignant-appearing-benign-lesion
#17
Jason N Butler, Todd T Kobayashi
Traumatic ulcerative granuloma with stromal eosinophilia (TUGSE) is an underreported diagnosis in dermatologic literature. Rapid expansion with an ulcerative clinical appearance often provokes fear of malignancy despite its benign nature. Traumatic ulcerative granuloma with stromal eosinophilia is thought to be a reactive tissue response to trauma, but CD30(+) mononuclear cells within a TUGSE lesion suggests the possibility of an underlying lymphoproliferative disorder. This case highlights the clinical and histological features of TUGSE and provides a brief review of the literature addressing this debate...
August 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28958786/-lymphomas-a-therapeutic-update
#18
A Wolfromm, R Delarue
Emergence of new molecules has considerably reshaped the management of patients in onco-hematology. Cytotoxic chemotherapy has not been altered, and CHOP remains the reference treatment for lymphomas. However, the development of targeted therapies has allowed for a broader spectrum of treatments. Immunotherapy with monoclonal antibodies entered the market with rituximab in diffuse large B-cell lymphomas, in the 1990s and it is now developing as new-generation anti-CD20 antibodies (obinotuzumab and ofatumumab)...
September 25, 2017: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/28952656/primary-cutaneous-cd30-lymphoproliferative-disorders-in-a-patient-with-severe-atopic-dermatitis-is-there-a-causative-link
#19
Magdalena Zychowska, Zdzislaw Wozniak, Joanna Maj
No abstract text is available yet for this article.
September 27, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28949403/brentuximab-vedotin-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma-who-are-ineligible-for-autologous-stem-cell-transplant-a-germany-and-uk-retrospective-study
#20
Paul J Bröckelmann, Erin A Zagadailov, Shelby L Corman, Viktor Chirikov, Courtney Johnson, Cynthia Macahilig, Brian Seal, Mehul R Dalal, Tim Illidge
OBJECTIVE: Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate licensed for the treatment of relapsed/refractory Hodgkin lymphoma (rrHL) following autologous stem cell transplant (ASCT) or at least two prior therapies when ASCT or multi-agent chemotherapy is not an option. The objective of this study was to describe real-world outcomes with BV in rrHL patients considered ASCT-ineligible or who refuse ASCT. METHODS: This was a retrospective medical chart review study that enrolled patients ≥18 years old who were initially diagnosed with HL between 1 January 2008 and 30 June 2014, considered ASCT-ineligible, and treated in routine care with BV for progressive disease after multi-drug chemotherapy regimens...
September 26, 2017: European Journal of Haematology
keyword
keyword
73698
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"